Clinical trial
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1…
NCT00097799 · Boehringer Ingelheim, Industry · Approved for marketing
Key facts
| NCT number | NCT00097799 |
|---|---|
| Title | Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection |
| Official title | An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program) |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tipranavir, Ritonavir |
| Start date | Dec 1, 2004 |
| Primary completion | Aug 1, 2005 |
| First posted | Dec 1, 2004 |
| Last update posted | Nov 30, 2016 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: